格隆汇8月11日｜国盛证券研报指出，汤臣倍健优化销售费用投放，盈利能力大幅改善。25Q2公司营收 降幅缩窄，除基数走低外，一方面受益于公司强化用户运营、提升销售转化，另一方面受益于公司加速 推新，线上推出高价格带产品，线下完善大众价格带布局。展望下半年，24H2公司收入端在消费力承 压、大单品新老品替换去库存、行业竞争加剧等影响下形成极低基数，25Q2-Q3公司新品陆续上市，并 将针对性匹配营销资源投入，预计25H2在极低基数、新品支撑下收入增速或迎转正，其中主品牌和 LSG仍有望成为拉动营收增长的主要驱动。利润端来看，公司将持续完善电商投放策略，加大对核心品 类升级品的投资，在抖音等兴趣电商或增加自播投入尝试，费投有望持续优化，贡献利润弹性，盈利能 力有望持续向好。 ...

国盛证券研报指出，汤臣倍健优化销售费用投放，盈利能力大幅改善。25Q2公司营收降幅缩窄，除基 数走低外，一方面受益于公司强化用户运营、提升销售转化，另一方面受益于公司加速推新，线上推出 高价格带产品，线下完善大众价格带布局。展望下半年，24H2公司收入端在消费力承压、大单品新老 品替换去库存、行业竞争加剧等影响下形成极低基数，25Q2-Q3公司新品陆续上市，并将针对性匹配营 销资源投入，预计25H2在极低基数、新品支撑下收入增速或迎转正，其中主品牌和LSG仍有望成为拉 动营收增长的主要驱动。利润端来看，公司将持续完善电商投放策略，加大对核心品类升级品的投资， 在抖音等兴趣电商或增加自播投入尝试，费投有望持续优化，贡献利润弹性，盈利能力有望持续向好。 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Views - The company experienced a significant decline in revenue, with a 23.4% year-on-year decrease in H1 2025, amounting to 3.53 billion yuan, while net profit decreased by 17.3% to 740 million yuan. However, Q2 2025 showed signs of recovery with a 71.4% increase in net profit compared to the previous year [1][4]. - The company is expected to narrow the revenue decline for the full year 2025, projecting a single-digit percentage decrease compared to H1 2025 [4]. Summary by Sections Financial Performance - In H1 2025, the main brand "汤臣倍健" generated 1.888 billion yuan in revenue, down 28.32% year-on-year. The "健力多" brand saw a 30.35% decline, generating 411 million yuan, while "Life-Space" domestic revenue fell by 34.43% to 138 million yuan. However, the overseas revenue for LSG increased by 13.46% to 534 million yuan [2]. - The company's gross margin for H1 2025 was 68.55%, slightly down from the previous year, while the net profit margin improved significantly to 21.61% due to effective cost control measures [3]. Cost Management - The sales expense ratio decreased by 4.59 percentage points in H1 2025, reflecting the company's efforts to control costs and reduce advertising expenditures. Management expenses increased slightly due to revenue decline, but overall profitability improved [3]. Future Outlook - The company plans to implement several initiatives to drive performance recovery, including product innovation and channel reform. New products are set to be launched in the second and third quarters of 2025, and the company aims to enhance its online sales and user engagement [4]. - Profit forecasts for 2025-2027 are set at 791 million, 921 million, and 1.024 billion yuan, respectively, with corresponding EPS of 0.46, 0.54, and 0.60 yuan, indicating a positive growth trajectory in the coming years [4].

Core Viewpoint - Tongrentang's revenue and net profit showed signs of recovery in the first half of 2025, driven by innovative products and operational improvements [1][2] Group 1: Financial Performance - In the first half of 2025, Tongrentang achieved a revenue of 3.532 billion yuan and a net profit of 737 million yuan [1] - The revenue decline in Q2 narrowed year-on-year, and net profit growth turned positive [1] Group 2: Market Trends and Product Strategy - The sales growth of dietary supplements in pharmacies declined by approximately 25% from January to May 2025 [1] - Tongrentang focuses on consumer-centric strategies, emphasizing basic nutrients with high penetration and frequency of purchase, while also enhancing high-quality functional products [1] - New products have shown growth, contributing to an increase in market share [1] Group 3: Product Performance - In May 2025, Tongrentang's protein powder, calcium DK, glucosamine, and Lifespace probiotics saw a sequential increase in market share due to new product launches [1] - Online, key products like the premium protein powder and liquid calcium ranked in the top 10 new products on Tmall during the "618" shopping festival [1] Group 4: Research and Development - Tongrentang is advancing its research in anti-aging, precision nutrition, and biosynthesis technologies [2] - Recent research findings on natural anti-aging components were published in the journal "Aging Cell," and Tongrentang was featured in "Nature" for its scientific achievements [2] Group 5: Future Outlook - According to Guosheng Securities, starting from Q2 2025, Tongrentang's performance is expected to improve gradually due to demand recovery, new product launches, and operational efficiency [2] - The company is also accelerating its expansion into overseas markets, which may contribute to performance stabilization and growth [2]

Summary of the Conference Call for汤臣倍健 Company Overview - **Company**:汤臣倍健 - **Industry**: Health Supplements Key Points and Arguments Financial Performance - In Q2 2025, the company reported a non-GAAP net profit growth of 133% year-on-year, indicating a significant recovery in profitability. However, the overall net profit for the first half of the year declined by 17.3% year-on-year [2][3] - Revenue for the first half of 2025 was 3.5 billion yuan, a year-on-year decrease of 23.4%. The decline in revenue narrowed to 11.5% in Q2 [3] - The company expects a single-digit decline in annual revenue, with the specific extent depending on Q3 performance [2][4] Product and Marketing Strategy - The company has been actively reforming its product, operations, and marketing strategies, achieving the highest product launch frequency in history during Q2 [2][3] - There is a focus on differentiating products between online and offline channels, with offline efforts centered on basic nutritional products and online on high-priced innovative products [2][3] - The main brand and Life Space Group (LSG) are expected to drive revenue growth in the second half of the year, with LSG showing particularly strong performance [7][8] Gross Margin and Cost Management - The gross margin for the first half of 2025 remained stable compared to the previous year, with a notable increase of 1.6 percentage points in Q2. Online gross margin improved significantly due to higher sales of high-margin products on platforms like JD.com [5][21] - The company has managed to control inventory and accounts receivable risks effectively, with proactive measures in place to mitigate potential issues [17] Brand Performance and Challenges - The健力多 brand faces uncertainties due to changes in leadership, new regulatory approvals, and product matrix optimization. Its online performance is better than offline, but conversion rates need continuous improvement [6][9] - The number of distributors decreased by approximately 140 in the first half of the year due to business adjustments and underperformance of new ventures [9] Market Trends and Competitive Landscape - The online sales environment remains competitive, with only JD.com showing growth among major platforms. Future efforts will focus on all key platforms, especially Douyin [13][24] - The company anticipates that online sales will outperform offline sales in the second half of the year, as online channels represent a growth market [15] New Product Development - New products such as盖 DK and high-concentration fish oil have performed well, contributing positively to sales and attracting new customers [18][26] - The company plans to continue optimizing new product promotions and expand production lines to meet diverse market demands [19] Future Outlook - The company aims for a revenue growth target of approximately 50% in the second half of the year, driven by marketing activities and new product launches [29] - Overall, the company expects net profit margins to improve slightly compared to the previous year, with management expenses remaining stable [32] Risks and Considerations - The rising price of whey protein (up 50% year-on-year) has limited impact on overall gross margins due to proactive supplier management [21] - The rapid growth of live-streaming e-commerce presents both opportunities and regulatory challenges, necessitating ongoing operational optimization [27] Additional Important Information - The company is focusing on the oral beauty segment targeted at young women, despite some underperformance in specific brands due to strategic choices [20] - The overall inventory situation among distributors has remained stable, with no significant trends in inventory reduction or accumulation [28]

Investment Rating - The investment rating for the company is "Maintain Buy" [6] Core Views - The company reported a significant improvement in profitability due to optimized sales expense allocation, with a notable recovery in net profit margins in Q2 2025 [2][3] - The revenue decline has narrowed, supported by enhanced user operations and new product launches, particularly in the high-price segment online and improved pricing strategies offline [1][2] - The company is expected to see revenue growth turn positive in H2 2025, driven by low base effects and contributions from new products [2][3] Financial Performance Summary - For H1 2025, the company achieved revenue of 3.53 billion yuan, a year-on-year decline of 23.4%, and a net profit of 740 million yuan, down 17.3% [1] - In Q2 2025, revenue was 1.74 billion yuan, a year-on-year decline of 11.5%, but net profit increased by 71.4% to 280 million yuan [1] - The gross margin for Q2 2025 improved by 1.7 percentage points to 68.4%, while the sales expense ratio decreased by 11.0 percentage points to 39.6% [2] - The net profit margin for Q2 2025 rose by 8.9 percentage points to 17.1%, indicating a significant improvement in profitability [2] Future Outlook - The company anticipates that the revenue growth will turn positive in H2 2025, supported by new product launches and strategic marketing resource allocation [2] - The forecast for net profit for 2025-2027 has been slightly adjusted to 830 million, 970 million, and 1.09 billion yuan respectively, reflecting a year-on-year growth of 26.7%, 17.5%, and 12.1% [3]

Core Insights - The company reported a decline in revenue and net profit for the first half of 2025, with a revenue of 3.532 billion yuan, down 23.43% year-on-year, and a net profit of 737 million yuan, down 17.34% year-on-year [1] - However, the second quarter of 2025 showed signs of recovery, with revenue of 1.741 billion yuan, a decrease of only 11.51% year-on-year, and a significant increase in net profit by 71.44% year-on-year [1][2] Revenue Performance - The overall revenue performance in the first half of 2025 was under pressure, but the decline in the second quarter was significantly narrowed compared to the first quarter [2] - In Q1 2025, the company achieved revenue of 1.792 billion yuan, down 32.29% year-on-year, while Q2 revenue was 1.741 billion yuan, down 11.51% year-on-year [2] - The main brand "汤臣倍健" generated revenue of 905 million yuan in Q2, down 17.0% year-on-year, while the international brand LSG saw a revenue increase of 12.4% year-on-year [2] Profitability and Cost Management - The gross margin improved in Q2 2025, with a gross margin of 68.43%, up 1.68 percentage points year-on-year [3] - The company significantly reduced its sales expense ratio in Q2 2025 to 39.65%, down 10.99 percentage points year-on-year, by optimizing its expense allocation and reducing advertising spending [3] - Advertising expenses for the first half of 2025 were 243 million yuan, down 53.49% year-on-year, contributing to the improved profitability [3] Business Development - The company made progress in its international and infant nutrition segments, expanding its presence in Southeast Asia and enhancing its brand "天然博士" for infant nutrition [4] - The company is focusing on brand upgrades and increasing its market influence while launching new products to create additional growth opportunities [4] Future Outlook - The company aims to enhance operational quality and optimize sales strategies in the second half of 2025, with new products expected to contribute positively to revenue [4] - Projections for net profit from 2025 to 2027 are 784 million yuan, 889 million yuan, and 1 billion yuan, representing year-on-year growth of 20%, 14%, and 12% respectively [4]

Investment Rating - The investment rating for the company is "Neutral" with a target price of 13.5 CNY [1][7]. Core Views - The company's revenue decline has narrowed, and cost control has improved performance. In the first half of 2025, the company achieved operating revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to the parent company of 737 million CNY, down 17.34% year-on-year. The second quarter saw a revenue of 1.741 billion CNY, a year-on-year decline of 11.51%, but a significant increase in net profit by 71.44% year-on-year [1][7]. Financial Performance Summary - **2025 Half-Year Report**: - Operating revenue: 3.532 billion CNY, down 23.43% YoY - Net profit: 737 million CNY, down 17.34% YoY - Q2 revenue: 1.741 billion CNY, down 11.51% YoY - Q2 net profit: 282 million CNY, up 71.44% YoY [1][7] - **Financial Projections**: - 2025E total revenue: 6.271 billion CNY, down 8.3% YoY - 2025E net profit: 811 million CNY, up 24.3% YoY - EPS for 2025E: 0.48 CNY [2][7]. Sales and Cost Management - The company has seen a significant reduction in sales expense ratio, which decreased by 11 percentage points to 39.6% in Q2 2025. This improvement is attributed to efficient spending and a shift towards higher-margin products [7][8]. - Gross margin for Q2 2025 was 68.4%, an increase of 1.7 percentage points year-on-year, driven by a higher proportion of premium products and improved online sales channel performance [7][8]. Market Outlook - The company plans to increase investment in the second half of 2025, with expectations for revenue to gradually improve. The strategy includes launching new products in key categories and focusing resources on profitable online channels [7][8]. - Despite a challenging external consumption environment, the company is expected to maintain a rational approach to spending, leading to a modest decline in annual revenue [7][8].

Core Viewpoint - The recent financial report of Tongchen Beijian (300146) indicates a decline in revenue and net profit for the first half of 2025, with significant changes in various financial metrics compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 3.532 billion yuan, a decrease of 23.43% year-on-year [1] - Net profit attributable to shareholders was 737 million yuan, down 17.34% year-on-year [1] - In Q2 2025, total revenue was 1.741 billion yuan, a decline of 11.51% year-on-year, while net profit for the quarter increased by 71.44% to 282 million yuan [1] - Gross margin stood at 68.55%, a slight decrease of 0.01% year-on-year, while net margin increased by 13.29% to 21.61% [1] - Total operating expenses were 1.448 billion yuan, accounting for 40.98% of revenue, a decrease of 7.78% year-on-year [1] - Earnings per share (EPS) was 0.43 yuan, down 17.31% year-on-year, while operating cash flow per share increased by 118.12% to 0.38 yuan [1] Accounts Receivable and Liabilities - Accounts receivable amounted to 504 million yuan, representing 77.24% of the latest annual net profit [1] - Interest-bearing liabilities surged by 6320.54% to 84.3 million yuan [1] Market and Business Model - The company's return on invested capital (ROIC) was 4.81% last year, indicating weak capital returns, with a historical median ROIC of 14% over the past decade [1] - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers of this approach [1] Analyst Expectations - Analysts project a net profit of 781 million yuan for 2025, with an average EPS estimate of 0.46 yuan [2] Fund Holdings - The largest fund holding Tongchen Beijian is the Manulife Consumer Dividend Index A, with 2.1437 million shares and a total size of 576 million yuan [3][4] - The fund has seen a 12.47% increase in value over the past year [4] Southeast Asia Market Focus - The company is currently focusing on the Southeast Asian market, particularly Indonesia, where it is in the process of obtaining market access [5]

Group 1: Financial Performance - The company's revenue decline in Q2 narrowed, and net profit increased year-on-year due to effective strategies in product and operations [1] - The gross margin remained stable compared to the same period last year, with a slight increase in Q2 due to changes in product and platform structure [1] - Online sales improved quarter-on-quarter in Q2, reflecting a stable pricing environment [5] Group 2: Market Trends and Competition - Market concentration is decreasing, with ongoing challenges from a sluggish offline market and intense online competition, particularly from interest e-commerce [2] - The company plans to enhance marketing resource allocation to expand offline product distribution in the second half of the year [2] Group 3: Brand and Product Development - The main brand and LSG are the primary contributors to revenue, with both showing good performance in product innovation and market expansion [3] - LSG's cross-border e-commerce accounts for approximately 70% of its sales, indicating its significance as a growth channel [4] - The company launched its first OTC product, "Jianliduo Sulfate Amino Glucosamine Capsules," in July, with plans for more products based on consumer demand [6] Group 4: Strategic Initiatives - The company aims to explore and optimize the business model for the Yep brand, focusing on attracting younger consumers online [7] - The company is adjusting its procurement strategies to mitigate the impact of raw material price fluctuations [9] - The decision to change the fundraising investment to a liquid bar production line is driven by the rapid growth of liquid beverage products [9]